Blood Cancer Journal www.nature.com/bcj

## CORRECTION OPEN



## Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of *JAK2*<sup>V617F</sup>-induced myeloproliferative neoplasms

Mengshi Hu, Tao Yang, Linyu Yang, Lu Niu, Jinbing Zhu, Ailin Zhao, Mingsong Shi, Xue Yuan, Minghai Tang, Jianhong Yang, Heying Pei, Zhuang Yang, Qiang Chen , Haoyu Ye, Ting Niu and Lijuan Chen

© The Author(s) 2024

Blood Cancer Journal (2024)14:104; https://doi.org/10.1038/s41408-024-01058-y

Correction to: *Blood Cancer Journal* (2022) 12:37 https://doi.org/10.1038/s41408-022-00628-2, published online 07 March 2022


Following the publication of this article, errors were noted in Figures 4G and 7A. Upon reviewing the original data, it was realized that H&E staining for the Fedra 30mg/kg in the Ba/F3-EPOR-JAK2<sup>V617F</sup> malignancy mouse model (Fig. 4G) was inaccurately analyzed as those from the *JAK2*<sup>V617F</sup>-induced MPN mouse model (Fig. 3D). This resulted in reuse of data from the Fedra 30mg/kg group. The corrected figure is presented below.

In Figure 7A, the image labeled 0.05  $\mu$ M for Patient 2# is incorrect. Upon comparing with the original data, an error was determined due to the fact that 2 images were captured for each concentration. The data marked as 0  $\mu$ M was mistakenly used in place of the 0.05  $\mu$ M data during organization. The accurate data for Patient 2# is presented below.

Published online: 26 June 2024


2

The authors confirm these changes have no impact on the conclusions of the study and apologize for any inconvenience caused by these errors.



**Fig. 4** Efficacy of FM against Ba/F3-EPOR-JAK2<sup>V617F</sup> malignancy mouse model. BALB/c-nude mice were intravenously injected with  $1.0 \times 10^6$  Ba/F3-EPOR-JAK2<sup>V617F</sup> –GFP cells and treated with vehicle, FM 15, 30, and 45 mg/kg and fedratinib 30 mg/kg bid. p.o. after 24 h, and the mice were sacrificed after 16 days of treatment. **A** Kaplan-Meier analysis of survival in Ba/F3-EPOR-JAK2<sup>V617F</sup> mice in vehicle and FM or fedratinib treatment groups (n = 7). **B** White blood cell counts in PB were analyzed (n = 5). **C** Circulating IL-6 and TNF-α levels were analyzed in blood serum by ELISA (n = 7). **D** Fluorescence-activated cell sorting (FACS) analysis of the percentage of GFP<sup>+</sup> cells in the PB at the end of the treatment (n = 7). **E** The size and weight of the spleen were acquired, and the spleen

suppression rate was evaluated (n=7). **F** Liver weights were analyzed (n=7). **G** Splenic architecture and the extent of myeloerythroid infiltration of the spleen and liver were observed in vehicle-treated animals compared to FM-treated animals. P-STAT3 and p-STAT5 levels were analyzed by IHC in the spleen. White pulp (yellow arrow), red pulp (green arrow), and tumor cell infiltration (green arrow) were marked. Images were obtained at  $\times 100$  and  $\times 200$  magnification. The histogram on the right panel is the quantitative statistics of IHC staining results performed by Image-Pro Plus. Data are represented as mean  $\pm$  SD, \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001 vs. vehicle, t-test.



**Fig. 7** Effects of FM on erythroid colony formation and JAK2/STAT signaling in MPN patient samples with activating *JAK2*<sup>V617F</sup> mutation. **A** Mononuclear cells were isolated from the PB or BM of patients with MPNs (Patient Number: 1#, 2#, and 3#), and incubated with FM in methylcellulose-based media. Hematopoietic colony-forming capacity was calculated by the total number of

BFU-E, CFU-M, and CFU-GEMM on day 14. **B** MPN patient cells (Patient Number: 2#, 4#, and 5#) were incubated with various concentrations of FM for 4 h, and the phosphorylation of STAT3 and STAT5 were analyzed via western blot analysis. Data are represented as mean  $\pm$  SD, \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001 vs. vehicle, t-test.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a>.

© The Author(s) 2024